The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma

[1]  C. Jones,et al.  Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Michael L. Wang,et al.  High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Hoster,et al.  Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.

[4]  R. Champlin,et al.  Long‐term follow‐up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission , 2003, Cancer.

[5]  K. Franssila,et al.  Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant , 2003, European journal of haematology.

[6]  T. Barbui,et al.  Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). , 2003, Blood.

[7]  D. Weisenburger,et al.  Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries , 2003, British journal of haematology.

[8]  R. Bouabdallah,et al.  Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study , 2002, Leukemia.

[9]  B. Dorken.  The Addition of Rituximab to Combination Chemotherapy With Fludarabine, Cyclophosphamide, Mitoxantrone—Results of a Prospective Randomized Comparison by the German Low Grade Study Group , 2002 .

[10]  J. Gribben,et al.  Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Kantarjian,et al.  Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Hagenbeek,et al.  Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Nathwani,et al.  A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. , 1995, Blood.

[14]  M. Engelhard,et al.  Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis , 1989, Hematological oncology.

[15]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .